

# Nurix Therapeutics, Inc. (NRIX)

Market Cap: \$1.3B

MAY 18, 2026 | CHICAGO & MILWAUKEE  
MAY 19, 2026 | NEW YORK



## Management

**Arthur T. Sands, M.D., Ph.D.**  
President, CEO and Board Director

**Jason Kantor, Ph.D.**  
Chief Business Officer

**Space will be limited. Meeting times and itinerary subject to change. To join the event or to obtain more information, please contact your Stephens sales representative.**

## About Nurix Therapeutics, Inc.

Nurix Therapeutics (NASDAQ: NRIX) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. NRIX has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell. NRIX is headquartered in San Francisco, CA.

## Roadshow Host

**Sudan Loganathan Ph.D**

Managing Director  
Biotechnology Research  
(212) 891-1762  
[Sudan.Loganathan@stephens.com](mailto:Sudan.Loganathan@stephens.com)